Last 31.50 GBp
Change Today -0.87 / -2.70%
Volume 21.3K
VER On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
OTC US
As of 7:15 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

vernalis plc (VER) Snapshot

Open
31.50 GBp
Previous Close
32.38 GBp
Day High
31.50 GBp
Day Low
31.50 GBp
52 Week High
01/6/14 - 38.00 GBp
52 Week Low
07/19/13 - 19.00 GBp
Market Cap
139.3M
Average Volume 10 Days
590.7K
EPS TTM
-0.0086 GBp
Shares Outstanding
442.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERNALIS PLC (VER)

Related News

No related news articles were found.

vernalis plc (VER) Related Businessweek News

No Related Businessweek News Found

vernalis plc (VER) Details

Vernalis plc, a research and development stage pharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson’s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; and Tris Pharma Inc. Vernalis plc is headquartered in Winnersh, the United Kingdom.

89 Employees
Last Reported Date: 03/31/14

vernalis plc (VER) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 610.0K GBP
Chief Financial Officer and Director
Total Annual Compensation: 417.0K GBP
Compensation as of Fiscal Year 2013.

vernalis plc (VER) Key Developments

Vernalis plc and Tris Pharma, Inc. Announce New Drug Application

Vernalis plc and Tris Pharma, Inc. announced that a new drug application has been submitted to the U.S. Food and Drug Administration for Tuzistra XR (CCP-01), for the acute treatment of cough cold. The FDA has 60 days in which to confirm whether the NDA is accepted for full review, and on receipt of this confirmation a milestone payment to Tris is triggered. CCP-01 represents the first product within this pipeline to reach NDA stage.

Vernalis plc Announces Encouraging Results from Phase Ib/II ADHD Study

Vernalis plc has announced results from a Phase Ib/II proof-of-concept, or POC, study of V81444, an A2A antagonist, in patients with attention deficit hyperactivity disorder, or ADHD. The randomised, double-blind, placebo controlled, two-period cross-over study was designed to evaluate the safety, tolerability and pharmacokinetics of V81444 dosed twice daily for 14 days and was conducted in adult patients with a confirmed diagnosis of ADHD. The study enrolled 31 patients and, in addition to evaluating safety, tolerability and pharmacokinetics, measured the efficacy of V81444 using the ADHD Rating Scale, PERMP-P and Clinical Global Impression (CGI) assessments. The efficacy assessments were conducted using the Adult Workplace Environment (AWE) model.

Vernalis plc, Annual General Meeting, May 23, 2014

Vernalis plc, Annual General Meeting, May 23, 2014., at 10:30 GMT Standard Time. Location: at the offices of Covington & Burling LLP.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 31.50 GBp -0.87

VER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 605.50 GBp -21.50
Richter Gedeon Nyrt 4,240 -65.00
Endo International PLC $67.25 USD 0.00
Impax Laboratories Inc $29.32 USD 0.00
Stada Arzneimittel AG €33.65 EUR -0.415
View Industry Companies
 

Industry Analysis

VER

Industry Average

Valuation VER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit www.vernalis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.